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Summary.-Forty-one adult patients with acute myelogenous leukaemia entered
remission induced by daunorubicin and cytosine arabinoside, and subsequently
received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine.
They were then randomized to either immunotherapy consisting of intradermal
BCG plus allogeneic cells or to "no maintenance". Patients receiving immuno-
therapy had significantly longer remission (P=0.039) and survival from remission
(P=0.044) as assessed by the log-rank test. The median duration of first remission
for 21 patients receiving immunotherapy was 35-14 weeks, compared with 19-71
weeks for 20 patients on no maintenance, and the median survival from remission
was doubled in patients receiving immunotherapy. The value of adequate consolida-
tion chemotherapy is confirmed by the comparatively long first remissions in both
groups compared with our previous trials, whilst avoidance of maintenance chemo-
therapy possibly allowed frequent second remissions and similar post-relapse
survival in patients from both treatment arms.
FOLLOWING Mathe&s (1969) encouraging
results with immunotherapy in acute
lymphoblastic leukaemia, and a similar
potential later shown in acute myelo-
genous leukaemia (Powles et al., 1971) we
initiated a pilot study of active immuno-
therapy used alone during remission in
adult patients with acute myelogenous
leukaemia (AML). This study, which
showed easy reinduction with consequent
prolongation of survival after relapse
(Freeman et al., 1973) was later followed
in Manchester by a randomized trial under
the aegis of the MRC which compared
immunotherapy with a combination of
immunotherapy and chemotherapy
(Harris et al., 1978a). This trial again
suggested that immunotherapy (when
givenwithout maintenance chemotherapy)
improved post-relapse survival. However,
a halving of first remission length com-
pared with the pilot study was attributed
to the omission of cytoreduction from the
MRC protocol. It was also unclear whether
immunotherapy itself was therapeutically
beneficial or whether its apparent advant-
ages were due to the avoidance of drug
resistance induced by maintenance chemo-
therapy. We designed our present trial to
remove these uncertainties. Consolidation
chemotherapy was reintroduced following
remission induced identically. Patients
were then randomized to either immuno-
therapy alone or a "no-maintenance arm".
This trial protocol allowed us for the first
time to assess the value ofimmunotherapy
uncomplicated by simultaneous mainten-
ance chemotherapy.
PATIENTS AND METHODS
From 1 January 1975 to 31 July 1978, 41
patients who entered complete and con-
solidated remission were randomized to re-
ceive either immunotherapy alone (RI, 21
patients) or "no maintenance" treatment
(RO, 20 patients). The follow-up of bothIMMUNOTHERAPY ALONE FOR AML
groups ofpatients is complete to 15 May 1979.
All patients were seen at weekly intervals for
clinical assessment and blood counts, whilst
marrow examinations were done at monthly
intervals. Marrows were reported on by a
number of different individuals, the majority
ofwhom were not aware ofthe treatment arm
to which the patient had been randomized.
Details ofinduction, criteria for remission and
relapse and administration of immuno-
therapy are described elsewhere (Freeman et
al., 1973; Harris et al., 1978a).
Statistical methods.-Although conventional
median values are given, Kaplan-Meier life
tables and log-rank analyses were used to
test the statistical significance of differences
in remission length and survival, using exact
variance calculations without continuity cor-
rections (Peto et al., 1977). Two-tailed P
values are quoted since this provides a more
rigorous test, making no prior assumptions in
favour ofimmunotherapy. Datawereanalysed
using a version of computer programme
SURV-C.
RESULTS
Data for each patient randomized are
given in detail in the Appendix. Four
different measures of outcome were ex-
amined:
1. Duration of first remission (all 41
patients: 21 RI, 20 RO).
2. Duration of survival from the date of
remission (all patients).
3. Duration of survival from the date of
first relapse (16 RI, 18 RO).
4. Duration of survival from the date of
start of induction chemotherapy (all
patients).
Table I summarizes the data relevant to
outcome in the patients randomized.
Corresponding life tables are shown in
Figs 1, 2 and 3, except for survival from
date of treatment, which is similar in
shape to that from first remission.
Duration offirst remission
The median remission length of 35-14
weeks in immunotherapy patients was
15-43 weeks (78%) longer than in the "no
maintenance" arm; this difference is
TABLE.-Summary ofresults
No. randomized
No. alive
No. in first remission
No. of second remissions
No. of third remissions
Median first remission
length (weeks)
Median survival from
remission (weeks)
Median survival after
relapse (weeks)
Median survival from
treatment (weeks)
1.0
0.8
> 0.6-
0 ir 0.4.
0.2
Trial arm
No
munotherapymaintenance
(RI) (RO)
21 20
9 3
5 2
9/16 7/18
2/9 1/7
35-14 19-71
90-29 45-71
28529 22-57
96-14 53 0
1500
FIG. 1.-Duration of first remission for 21
patients randomized to immunotherapy
( ~) and 20 to no maintenance (.. ),
(P=0.039. (0) and (V) indicate patients
still in first remission.
statistically significant (X2 = 4-26, P=
0.039) with a halving in the relapse-rate
ratio (0.51). Five RI patients (24%) are
still in their first remission, and of these 2
have achieved remission lengths greater
than 3- years, one over 2 years and 2 over
12 years. Fourteen of 21 RI patients (66%)
have achieved remission lengths greater
than 6 months, in contrast to the RO
patients, only 5/20 (25%) of whom
achieved remission of 6 months or more.
Only 2 (10%) of RO patients are still in
their first remission although both have
now achieved more than 3 years.
300 600 900 1200
DAYS
I ~ ~ ~ ~ ~ ~ ~ ~~~~~~ * * *_
373
i
I
I 0-
......:
....................................374 ~~~~~~S. R. ZUHRIE ET AL,
1.0 0.345) with me~dians of 28-29 and 22-57
weeks for immunotherapy and "no main-
0 ~~~~~~~~~~tenance" patients respectively.
Duration of survivalfrom date of treatment
Patients receiving immunotherapy had
L~~~~~~~ median survival of 96 14 weeks com-
0. pared with 53 weeks for RO (X2=399,
P= 0.045) with a halving in the death-rate
ratio (0-48).
0.2
. ~~~....... DISCUSSION
______________________ --__
The literature describing the use of
300 600 900 iioo m'oo iMMunotherapy in patients with acute
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Fia. 2.-Duration ofsurvival from first remis- mylgnulekmi(ALisxt-
sion for 21 patients randomized to sive (reviewed by Murphy & Hersh, 1978)
immunotherapy ( ~)and 20 to no main- and we cite only a few illustrative reports tenance (....), P=0-044. (0) and (V) i hsdsuso.Mn ifrn muo indiate atiets sill urviing.therapy regimens have been used, and it is
1.0 difficult or even impossible to compare
them. Furthermore, many claims for the
0.8 ~~~~~~~efficacy of immunotherapy have been 0.8 ~~~~~~~weakened by serious shortcomings in
experimental design. Thus, some reports 0.6 ~~~~~~~~~do not include data on suitable controls or
the controls have not been randomized.
00 When controls have received immuno-
therapy and simultaneous chemotherapy,
the effects of these forms of treatment
0. ~~~~~~~~~cannot be separated (Powles et al., 1979).
In some trials the comparative value of
_________________________ controls hias been negated because they
300 600 900 1200o 1500 have fared particularly badly in com-
DAYS prsnwt ainsi te ulse
FIG. 3.-Duration of survival after first parieson with patients inother pubiseldha relapse for 16 patients randomized to sre.Oronwr nti il a
immunotherapy ( ) and iS to no main- suffered in the past from some of these
tenance (....). P=0-345. (0) and (V) sotoig.Orfrttilwsitne
indicate patients surviving on immuno- beoracpilot. study ands tinclue nos controle
therapy and no maintenance respectively, to b io td n nlddn oto
patients (Freeman et al., 1973). In our
Duration of survivalfrom remission second trial (Harris et al., 1978a) we
Themedan urvva of90-9 weksin deleted consolidation chemotherapy in Tha mdinourvo Iaivals cofpare9weeksin7 accordance with the MRC protocol (MRC,
favs ouro RI patients: copaeswithreci57 1978) and so reduced first-remission length
westa foricaRO patieicnts the2diferenc
is that interpretation was difficult. A further
statiswticall saignificnthex death Pate complication was the randomization
0ato.044)8iha
avn i h eahrt (according to the MRC (1978) protocol) to
ratio (0.48). ~~remission maintenance with immuno-
Durtio o 8uvivl ftefirt elase therapy alone or immunotherapy with Durtio ofsuvivl aterfist elase simultaneous chemotherapy which we
The difference between RI and RO now believe interferes with the effects of
patients is not significant (X2 = 089, P = immunotherapy.
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We designed our third trial so as to over-
come these problems. Firstly, we re-
introduced a consolidation phase after
induction chemotherapy, in an attempt to
further reduce leukaemic cell mass. We
then randomized patients to one of 2
therapeutic arms; immunotherapy alone
(RI) or "no maintenance" (RO). It was
then possible to assess the value of
immunotherapy in patients in remission
with minimum leukaemic cell mass and
uncomplicated by simultaneous chemo-
therapy. Over a follow-up period varying
from 10 months to 4 years, immuno-
therapy patients in this trial have had
significantly longer remissions and survival
than patients receiving no maintenance
treatment. It is also noteworthy that there
was no overt CNS involvement in patients
on immunotherapy, compared with 3 RO
patients with leukaemic CNS disease,
although Peto et al. (1977) have indicated
the difficulties in the analysis of CNS
involvement. Ourimmunotherapypatients
fared as well as those of Powles et al.
(1977b) who used a "superior" form of
immunotherapy (BCG and cells mixed
together), both in terms of length of first
remission and in the proportion remaining
in remission for more than 2 years. It is
particularly encouraging that the signifi-
cant differences between our RI and the
RO patients appear to be genuine, and not
due to unusually poor remission lengths
or durations of survival in the controls.
For example, the RO median remission
length of almost 20 weeks is comparable
with chemotherapy medians in other
studies (Reizenstein et al., 1978; MRC,
1978) while the median of 22 weeks for
survival after relapse in the RO group is
similar to that reported by the MRC (1978)
for patients receiving immunotherapy
plus maintenance chemotherapy, and is
better than chemotherapy medians (MRC,
1978, 1979).
In this trial second-remission rates and
post-relapse survival are similar in RO and
RI patients, confirming our original sug-
gestion (Freeman et al., 1973) that the
poor post-relapse performance of RI plus
chemotherapy (referred to as I+ C) com-
pared with RI may have been partly due
to mnaintenance chemotherapy. Indeed,
the results of our present (third) trial
suggest that maintenance chemotherapy
may worsen the outlook for patients who
relapse and should, unless otherwise indi-
cated, be omitted. Thus, although RI
patients had significantly longer first
remissions and survival than RO patients,
there was no significant difference between
RI and RO in terms of post-relapse sur-
vival orsecond-remission rates, whilst both
groups of patients have done better than
would be expected from the published data
on post-relapse performance of patients
receiving maintenance chemotherapy
(Powles et al., 1977a; Whittaker & Slater,
1977; Gale & Cline, 1977; MRC, 1978,
1979). We suggest that chemotherapy
seems unnecessary for maintenance if
adequate induction and consolidation
treatment has been given, and is better
reserved for reinduction after first relapse,
detected early by monthly marrow ex-
amination whilst the leukaemic cell mass
is still small (Harris et al., 1978a). In our
opinion, based on 8 years' experience of
immunotherapy in AML, there is no
ethical objection to the omission of main-
tenance chemotherapy, so long as no form
of treatment is available which will selec-
tively ablate all leukaemic cells.
The value of consolidation chemo-
therapy emerges from a comparison ofthis
with our earlier trials. Thus, first-remission
length was reduced to 11-5 weeks in the
immunotherapy-alone arm of our second
trial (Harris et al., 1978a) in which con-
solidation chemotherapy was not used,
and should be compared with our trials
which did include consolidation, notably
the superior results of 23 weeks in the
first trial (Freeman et al., 1973) and 35-14
weeks in the present trial.
It has been emphasized (MRC, 1978)
that rapid changes may occur in small
trials as patients relapse or die. However,
this tendency decreases the longer patients
remain in remission (Freirich et al., 1978)
and our results, taken with those ofothers,
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confirm thatimmunotherapy doesprolong
first remission and survival. However, it
may fairly be asked whether the definite
but modest improvements attributable to
immunotherapy justify the considerable
logistic problems involved. We have no
doubt ofthe heuristic value ofthese trials,
which justifies further work to identify
and explain the underlying immuno-
pathological mechanism. In this connec-
tion we agree withMurphy & Hersh (I978)
who emphasize the need for better forms
of immunotherapy, and our studies of
genetic markers in AML (Harris et al.,
1977. 1978b) convince us that certain
categories of AML patients will respond
better than others. As a result of ourtrials,
we further suggest that maintenance
chemotherapy as currently used may
actually worsen prognosis, as well as
rendering unacceptable the quality of life
of many AML patients.
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APPENDIX
Datafor 41 patients entered into Manchester third trial (to 15 May 1979)
No. Sex
1 F
2 M
3 M
4 F
5 F
6 M
7 F
8 F
9 M
10 M
11 M
12 M
13 M
14 F
15 F
16 F
17 F
18 F
19 F
20 F
21 F
22 M
23 F
24 F
25 F
26 M
27 M
28 F
29 M
30 F
31 F
32 F
33 F
34 M
35 M
36 F
37 F
38 M
39 F
40 F
41 F
Age
56
18
35
28
55
53
55
44
32
21
32
53
61
24
57
39
68
30
19
58
63
63
44
25
29
47
33
34
48
61
58
20
50
15
33
38
20
23
56
47
21
Diagnosis
AML
EL
AMOL
APL
AMML
AML
AML
AML
AML
AMML
AML
AMML
AML
APL
AML
EL
AMOL
AMML
AML
AML
AML
AMML
AML
AML
EL
AMML
AMML
AMOL
AML
AML
EL
AML
AMML
EL
AMML
AML
AMOL
AML
AML
AML
APL
Treatment
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RI
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
RO
First
remission
(days)
107
94
1436*
457
109
246
127
330
532*
175
244
1233*
205
268
99
973
217
140
868*
456
642*
85
165
95
1314*
71
173
1120*
168
67
151
131
161
129
119
130
90
261
237
138
361
Survival
after
relapse
(days)
39
201
474
169
198
36
302
344
244
83
41
150
19
244
141
193
84
442
95
36
147
173
130
266
166
244
375
330
81
31
247
32
158
25
Survival
from
remission
(days)
146
295
1436 A
931
278
444
163
632
532 A
519 A
488 A
1233 A
288
309
249
992 A
461
281
868 A
649 A
642 A
169
607
190
1314 A
107
320
1120 A
341
197
417
297
405
504
449
211
121
508
269
296
386 A
* =Still in first remission.
A=Alive.
AML=Acute myeloblastic leukaemia.
AMML =Acute myelomonocytic leukaemia.
AMOL =Acute monoblastic/monocytic leukaemia.
APL=Acute promyelocytic leukaemia.
EL =Erythroleukaemia.
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